KROS
Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.32
+1.89%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 13.93x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 0.86x
- Price / sales
- 14.95x
- Price / cash flow
- -4.68x
Enterprise value
- Enterprise value
- -$17.4M
- EV / sales
- -1.16x
- EV / EBITDA
- 0.21x
- EV / EBIT
- 0.17x
- Market cap
- $224.4M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026